JP2023551279A5 - - Google Patents
Info
- Publication number
- JP2023551279A5 JP2023551279A5 JP2023532456A JP2023532456A JP2023551279A5 JP 2023551279 A5 JP2023551279 A5 JP 2023551279A5 JP 2023532456 A JP2023532456 A JP 2023532456A JP 2023532456 A JP2023532456 A JP 2023532456A JP 2023551279 A5 JP2023551279 A5 JP 2023551279A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- viral vector
- nucleic acid
- aav
- muscular dystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119268P | 2020-11-30 | 2020-11-30 | |
| US63/119,268 | 2020-11-30 | ||
| PCT/US2021/061109 WO2022115745A1 (en) | 2020-11-30 | 2021-11-30 | Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551279A JP2023551279A (ja) | 2023-12-07 |
| JP2023551279A5 true JP2023551279A5 (enExample) | 2024-11-14 |
Family
ID=79021122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532456A Pending JP2023551279A (ja) | 2020-11-30 | 2021-11-30 | 顔面肩甲上腕筋ジストロフィー（ｆｓｈｄ）を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240026356A1 (enExample) |
| EP (1) | EP4251752A1 (enExample) |
| JP (1) | JP2023551279A (enExample) |
| KR (1) | KR20230128470A (enExample) |
| AU (1) | AU2021385595A1 (enExample) |
| CA (1) | CA3203585A1 (enExample) |
| IL (1) | IL303230A (enExample) |
| WO (1) | WO2022115745A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP2022516515A (ja) * | 2018-12-31 | 2022-02-28 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US20230279397A1 (en) | 2022-03-04 | 2023-09-07 | Locanabio, Inc. | Compositions and methods comprising engineered short nuclear rna (snrna) |
| WO2025225719A1 (en) * | 2024-04-26 | 2025-10-30 | Chugai Seiyaku Kabushiki Kaisha | Treatment and prevention of muscular dystrophy and its related diseases or disorders with satralizumab |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたａａｖベクター |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP1696036B1 (en) | 1996-09-06 | 2010-04-21 | The Trustees of The University of Pennsylvania | Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells |
| CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| CA2842798C (en) | 2011-07-25 | 2021-02-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| JP6966463B2 (ja) * | 2016-02-26 | 2021-11-17 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 組換えウイルス産物及びｄｕｘ４エクソンスキッピングを誘導するための方法 |
| WO2020028134A1 (en) * | 2018-07-30 | 2020-02-06 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating cancer |
| JP2022516515A (ja) * | 2018-12-31 | 2022-02-28 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止 |
-
2021
- 2021-11-30 CA CA3203585A patent/CA3203585A1/en active Pending
- 2021-11-30 WO PCT/US2021/061109 patent/WO2022115745A1/en not_active Ceased
- 2021-11-30 JP JP2023532456A patent/JP2023551279A/ja active Pending
- 2021-11-30 EP EP21830568.8A patent/EP4251752A1/en active Pending
- 2021-11-30 IL IL303230A patent/IL303230A/en unknown
- 2021-11-30 AU AU2021385595A patent/AU2021385595A1/en active Pending
- 2021-11-30 US US18/038,878 patent/US20240026356A1/en active Pending
- 2021-11-30 KR KR1020237022057A patent/KR20230128470A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024095717A5 (enExample) | ||
| JP2020518266A5 (enExample) | ||
| FI3596222T3 (fi) | Lihasspesifisen mikrodystrofiinin adenoassosioitu virusvektori -kuljetus lihasdystrofian hoitamiseksi | |
| JP2021502060A5 (enExample) | ||
| RU2018137677A (ru) | Модифицированная промоторная система u6 для тканеспецифической экспрессии | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2019519218A5 (enExample) | ||
| FI3807413T3 (fi) | Lihasspesifisen mikrodystrofiinin annostelu adeno-assosioituneella virusvektorilla lihasdystrofian hoitamiseksi | |
| JP2019519219A5 (enExample) | ||
| RU2016101198A (ru) | Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов | |
| JP2019515663A5 (enExample) | ||
| WO2011101869A1 (en) | Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer | |
| RU2016101178A (ru) | Доставка, конструирование и оптимизация систем, способы и композиции для целенаправленного воздействия и моделирования заболеваний и нарушений постмитотических клеток | |
| RU2016101200A (ru) | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени | |
| JP2022516515A5 (enExample) | ||
| BR112012033363A2 (pt) | vacina de tumor recombinante e método de produção de tal vacina | |
| JP2021525531A5 (enExample) | ||
| JP7546295B2 (ja) | ヒトアンジェルマン症候群において父方ｕｂｅ３ａ遺伝子発現を復活させるための組成物および方法 | |
| JP2023553005A5 (enExample) | ||
| JP2021534755A5 (enExample) | ||
| JP2022501044A5 (enExample) | ||
| JP2021534794A5 (enExample) | ||
| JP2022522166A5 (enExample) | ||
| JP2020527167A5 (enExample) | ||
| JP2023506842A5 (enExample) |